GLAXOGlaxosmithkline Phar

₹2658.5-0.91%

Market Cap

₹45,087.42 Cr

Stock P/E

47.45

ROCE

67.64%

ROE

49.43%

Book Value

₹128.17

Financials

YoY Net Sales

EPS Growth

Operating Margin

No recent news available for this stock.

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

POSITIVES

•
Q1 competitive performance was held and growth is ahead of the market.
•
Oncology launches Zejula and Jemperli are in motion with sizable addressable patient populations in India.

NEGATIVES

•
Q1 growth was muted due to softer tailwinds and external headwinds.
•
External growth was muted in certain therapy areas (derm and anti-infectives) with supply/trends impacting performance.

Peer comparison data is not available for this stock.